Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.
Peripheral metabolism of L-DOPA via enzyme catechol-O-methyltransferase (COMT) is one of the possible sources of homocysteine (HCY). The aim of this study was to assess plasma HCY levels in L-DOPA-treated Parkinson's disease (PD) patients and its influence by adding the inhibitor COMT (entacapone). Patients were divided into two groups: (1) patients long term treated with L-DOPA but were naïve to entacapone, (2) L-DOPA naïve patients, in whom a combined treatment with L-DOPA and entacapone was started. The HCY levels were higher in Group 1 than in Group 2. No statistically significant changes of HCY concentrations were found in both patient groups after adding entacapone to their L-DOPA treatments. Results of this study confirm that patients treated with L-DOPA for a long term have increased plasma HCY concentrations. We believe combined L-DOPA and entacapone therapy could be a possible protective mechanism against hyperhomocysteinemia in early PD.
Nevrly
Martin
M
Department of Neurology, University Hospital and Palacký University Medical School, I. P. Pavlova 6, 77520, Olomouc, Czech Republic. nevrly.martin@post.cz
Kanovsky
Petr
P
Vranova
Hana
H
Langova
Katerina
K
Hlustik
Petr
P
D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002396:Catechols / Q000627:therapeutic use*; D005260:Female; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000097:blood* / Q000188:drug therapy*; D013997:Time Factors
D000978:Antiparkinson Agents; D002396:Catechols; D009570:Nitriles; D006710:Homocysteine; D007980:Levodopa; C071192:entacapone
Nutr Rev. 2002 Dec;60(12):410-3
12521146
J Neural Transm Suppl. 1993;39:165-72
8360656
N Engl J Med. 1995 Feb 2;332(5):286-91
7816063
Am J Hum Genet. 1998 Nov;63(5):1541-3
9792881
Lancet. 1995 Nov 25;346(8987):1395-8
7475822
Parkinsonism Relat Disord. 2005 Mar;11(2):131-3
15734674
N Engl J Med. 2002 Feb 14;346(7):476-83
11844848
Acta Neurol Scand. 2003 Jul;108(1):66-7
12807397
Neurotoxicology. 1995 Fall;16(3):527-9
8584284
Clin Chem. 2001 Jun;47(6):1102-4
11375298
Arterioscler Thromb. 1991 Sep-Oct;11(5):1129-36
1911700
Lancet. 1999 Jul 10;354(9173):126-7
10408491
Eur Neurol. 1998 Nov;40(4):225-7
9813406
Acta Neuropathol. 2003 May;105(5):415-9
12677440
Annu Rev Nutr. 1999;19:217-46
10448523
Eur J Pediatr. 1998 Apr;157 Suppl 2:S40-4
9587024
Clin Chem Lab Med. 2003 Nov;41(11):1392-403
14656016
Parkinsonism Relat Disord. 2005 Jun;11(4):253-6
15878587
Mov Disord. 2004 Dec;19(12):1403-8
15390053
Eur J Neurol. 2005 May;12(5):365-8
15804266
Neurology. 2002 Dec 10;59(11):1708-13
12473757
Cardiovasc Drugs Ther. 2002 Sep;16(5):391-9
12652108
Neurology. 2000 Aug 8;55(3):437-40
10932284
Arch Neurol. 2003 Jan;60(1):59-64
12533089
Neurol Res. 2006 Dec;28(8):853-8
17288745
Neurology. 2003 Apr 8;60(7):1125-9
12682318
Lancet Neurol. 2003 Jul;2(7):425-8
12849121
Neurology. 2005 Apr 26;64(8):1482
15851757
N Engl J Med. 1998 Apr 9;338(15):1042-50
9535670
J Neurol Sci. 2003 Mar 15;207(1-2):19-23
12614926
Trends Neurosci. 2003 Mar;26(3):137-46
12591216
Clin Chem. 2004 Jan;50(1):3-32
14709635
J Nutr. 2000 Dec;130(12):3073-6
11110872